X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4903) 4903
Conference Proceeding (30) 30
Dissertation (25) 25
Book Chapter (24) 24
Magazine Article (5) 5
Publication (5) 5
Book / eBook (4) 4
Paper (4) 4
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adamantane - analogs & derivatives (2513) 2513
humans (1727) 1727
animals (1397) 1397
adamantane - pharmacology (1277) 1277
adamantane (1229) 1229
male (1047) 1047
adamantane - chemistry (783) 783
female (710) 710
adamantane - therapeutic use (671) 671
pharmacology & pharmacy (594) 594
diabetes mellitus, type 2 - drug therapy (587) 587
mice (553) 553
chemistry, organic (548) 548
rats (530) 530
chemistry, multidisciplinary (509) 509
chemistry (424) 424
middle aged (397) 397
adamantane - administration & dosage (356) 356
biochemistry & molecular biology (353) 353
dipeptidyl-peptidase iv inhibitors - therapeutic use (351) 351
chemistry, medicinal (345) 345
analysis (340) 340
hypoglycemic agents - therapeutic use (340) 340
adamantane - chemical synthesis (335) 335
type 2 diabetes (331) 331
endocrinology & metabolism (329) 329
chemistry, physical (308) 308
adamantane - adverse effects (297) 297
molecular structure (297) 297
pyrrolidines - therapeutic use (294) 294
derivatives (291) 291
aged (290) 290
vildagliptin (286) 286
nitriles - therapeutic use (285) 285
adult (281) 281
structure-activity relationship (261) 261
treatment outcome (256) 256
dose-response relationship, drug (254) 254
models, molecular (229) 229
diabetes (225) 225
research (222) 222
antiviral agents - pharmacology (221) 221
drug therapy, combination (219) 219
diabetes mellitus, type 2 - blood (209) 209
dipeptides - therapeutic use (196) 196
adamantane resistance (191) 191
pyrrolidines - pharmacology (189) 189
adamantane - pharmacokinetics (183) 183
adamantane derivatives (182) 182
influenza (182) 182
dipeptidyl-peptidase iv inhibitors - adverse effects (177) 177
metformin (177) 177
nitriles - pharmacology (176) 176
cell line, tumor (175) 175
dipeptidyl-peptidase iv inhibitors - pharmacology (175) 175
hypoglycemic agents - adverse effects (174) 174
glucagon-like peptide-1 (171) 171
adamantane - metabolism (170) 170
in-vitro (168) 168
blood glucose - metabolism (164) 164
saxagliptin (162) 162
amantadine (160) 160
double-blind method (160) 160
organic chemistry (158) 158
time factors (156) 156
enzyme inhibitors - pharmacology (153) 153
ligands (152) 152
blood glucose - drug effects (151) 151
hypoglycemic agents - administration & dosage (151) 151
glucose (150) 150
pyrrolidines - adverse effects (148) 148
adamantanes (147) 147
rats, sprague-dawley (147) 147
rats, wistar (147) 147
nitriles - adverse effects (145) 145
drug therapy (140) 140
antineoplastic agents - pharmacology (138) 138
glycated hemoglobin a - metabolism (138) 138
efficacy (137) 137
inhibitors (137) 137
administration, oral (136) 136
care and treatment (136) 136
kinetics (135) 135
apoptosis (134) 134
cell line (134) 134
influenza a virus - drug effects (134) 134
design (132) 132
neurosciences (131) 131
pyrrolidines - administration & dosage (130) 130
nitriles - administration & dosage (128) 128
chemical properties (127) 127
chemistry, inorganic & nuclear (125) 125
dipeptides - adverse effects (125) 125
polymer science (125) 125
synthesis (125) 125
activation (124) 124
hydrocarbons (123) 123
health aspects (122) 122
in vitro techniques (122) 122
dipeptidyl-peptidase iv inhibitors - administration & dosage (120) 120
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4614) 4614
Russian (241) 241
German (58) 58
Japanese (53) 53
French (22) 22
Chinese (19) 19
Czech (8) 8
Spanish (8) 8
Italian (6) 6
Ukrainian (5) 5
Hungarian (4) 4
Polish (4) 4
Portuguese (4) 4
Croatian (3) 3
Korean (3) 3
Swedish (2) 2
Bulgarian (1) 1
Dutch (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Toxicon, ISSN 0041-0101, 12/2018, Volume 156, pp. S49 - S50
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2011, Volume 108, Issue 11, pp. 4400 - 4405
Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase... 
Artemisinins | Malaria | Half lives | Antimalarials | Peroxides | Parasites | Dosage | Ozonides | Blood | Blood plasma | 1,2,4-trioxolane | Antimalarial drug discovery | OZ277 | PHARMACODYNAMIC PROPERTIES | MULTIDISCIPLINARY SCIENCES | ARTEROLANE | TRIOXOLANE | 1-AMINOBENZOTRIAZOLE | antimalarial drug discovery | PEROXIDES | IN-VITRO ASSESSMENT | PLASMODIUM-FALCIPARUM | ANTIMALARIAL ACTIVITY | ARTEMISININ | Peroxides - administration & dosage | Plasmodium berghei - physiology | Male | Peroxides - therapeutic use | Peroxides - pharmacokinetics | Dose-Response Relationship, Drug | Artemisinins - pharmacology | Heterocyclic Compounds - chemistry | Time Factors | Adamantane - therapeutic use | Adamantane - administration & dosage | Adamantane - pharmacokinetics | Artemisinins - chemistry | Adamantane - analogs & derivatives | Antimalarials - pharmacokinetics | Heterocyclic Compounds - administration & dosage | Drug Stability | Peroxides - chemistry | Rats | Treatment Outcome | Antimalarials - therapeutic use | Iron - metabolism | Rats, Sprague-Dawley | Animals | Artemisinins - therapeutic use | Antimalarials - administration & dosage | Antimalarials - chemistry | Malaria - parasitology | Heterocyclic Compounds - pharmacokinetics | Mice | Adamantane - chemistry | Heterocyclic Compounds - therapeutic use | Malaria - drug therapy | Care and treatment | Composition | Health aspects | Malaria vaccine | Biological Sciences
Journal Article
Diabetes care, ISSN 1935-5548, 2009, Volume 32, Issue 9, pp. 1649 - 1655
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone Ralph A.... 
ORAL GLUCOSE-TOLERANCE | POTENT | MONOTHERAPY | GLUCAGON-LIKE PEPTIDE-1 | GLYCEMIC DURABILITY | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | INHIBITOR | Metformin - therapeutic use | Humans | Middle Aged | Male | Metformin - adverse effects | Young Adult | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Placebos | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Dipeptides - pharmacology | Metformin - pharmacology | Treatment Outcome | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Dipeptides - administration & dosage | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Diabetics | Medical research | Care and treatment | Medicine, Experimental | Glucose | Pharmaceutical industry | Dextrose | Diabetes therapy | Heart failure | Physical examinations | Drug abuse | Substance abuse treatment | Research methodology | Patient care planning | Diabetes | Safety | Drug therapy | Hypoglycemia | Apoptosis | Index Medicus | Original Research
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent)
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 1, pp. 61 - 69
Journal Article
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 130, Issue 18, pp. 1579 - 1588
Journal Article